Resonance Health Limited

Symbol: RHT.AX

ASX

0.077

AUD

Market price today

  • -32.9395

    P/E Ratio

  • -1.4823

    PEG Ratio

  • 34.41M

    MRK Cap

  • 0.00%

    DIV Yield

Resonance Health Limited (RHT-AX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

1.01%

Operating Profit Margin

-0.26%

Net Profit Margin

-0.20%

Return on Assets

-0.10%

Return on Equity

-0.11%

Return on Capital Employed

-0.15%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO:Mr. Andrew Duncan Harrison BCom (Hons), MAICD
Full-time employees:18
City:Burswood
Address:141 Burswood Road
IPO:2000-01-02
CIK:

Resonance Health Limited, a healthcare technology and services company, designs, develops, and manufactures software-as-medical devices in the Asia Pacific, North America, South America, Europe, the Middle East, and Africa. It offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-assisted device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also offers quantitative imaging measurements and CRO, such as quality-assured image analysis, imaging charter development, project and data management, issue resolution, site tracker and clinical trial progress report, and coordination of data flow services; biomarkers, blood, urine, and protein analytes, as well as RNA, DNA, and genotyping services; and protocol development, assessment of subject inclusion or exclusion, decisions on dose modifications, and evaluating the safety profile of a new therapy, as well as supporting primary and secondary end-points demonstrating drug efficacy services for multinational and multicenter clinical trials; and phantoms for the calibration of MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.

General Outlook

When we look at how much money they make before expenses, they keep 1.012% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.261%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.195%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.099% return, is a testament to Resonance Health Limited's adeptness in optimizing resource deployment. Resonance Health Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.110%. Furthermore, the proficiency of Resonance Health Limited in capital utilization is underscored by a remarkable -0.145% return on capital employed.

Stock Prices

Resonance Health Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.061, while its low point bottomed out at $0.055. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Resonance Health Limited's stock market.

Liquidity Ratios

Analyzing RHT.AX liquidity ratios reveals its financial health of the firm. The current ratio of 825.17% gauges short-term asset coverage for liabilities. The quick ratio (804.91%) assesses immediate liquidity, while the cash ratio (662.90%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio825.17%
Quick Ratio804.91%
Cash Ratio662.90%

Profitability Ratios

RHT.AX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -20.49% underscores its earnings before tax deductions. The effective tax rate stands at 4.82%, revealing its tax efficiency. The net income per EBT, 95.18%, and the EBT per EBIT, 78.38%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -26.14%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-20.49%
Effective Tax Rate4.82%
Net Income per EBT95.18%
EBT per EBIT78.38%
EBIT per Revenue-26.14%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 8.25, it details the span from stock purchase to revenue. The 8 days it takes to settle debts showcases its creditor relations. Meanwhile, a 7 cash conversion cycle and 440.83% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding805
Operating Cycle82.79
Days of Payables Outstanding-3746
Cash Conversion Cycle3829
Receivables Turnover4.41
Payables Turnover-0.10
Inventory Turnover-67000.00
Fixed Asset Turnover6.67
Asset Turnover0.51

Cash Flow Ratios

The cash per share value, 0.01, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.05, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Cash per Share0.01
Operating Cash Flow Sales Ratio-0.05
Free Cash Flow to Operating Cash Flow Ratio2.62
Cash Flow Coverage Ratio-0.82
Short Term Coverage Ratio-2.06
Capital Expenditure Coverage Ratio-0.62
Dividend Paid and Capex Coverage Ratio-0.62

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.94%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.03, we discern the balance between debt and equity financing. The long-term debt to capitalization, 1.93%, and total debt to capitalization, 3.16%, ratios shed light on its capital structure.

cards.indicatorcards.value
Debt Ratio2.94%
Debt Equity Ratio0.03
Long Term Debt to Capitalization1.93%
Total Debt to Capitalization3.16%
Cash Flow to Debt Ratio-0.82
Company Equity Multiplier1.11

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.01, provides a glimpse into top-line earnings distributed across each share. The book value per share, 0.02, represents the net asset value distributed per share, while the tangible book value per share, 0.02, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.01
Book Value Per Share0.02
Tangible Book Value Per Share0.02
Shareholders Equity Per Share0.02

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 15.06%, indicates top-line expansion, while the gross profit growth, 15.06%, reveals profitability trends. EBIT growth, 10.10%, and operating income growth, 10.10%, offer insights into operational profitability progression. The net income growth, 31.65%, showcases bottom-line expansion, and the EPS growth, 32.00%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth15.06%
Gross Profit Growth15.06%
EBIT Growth10.10%
Operating Income Growth10.10%
Net Income Growth31.65%
EPS Growth32.00%
EPS Diluted Growth32.00%
Operating Cash Flow Growth77.97%
Free Cash Flow Growth55.89%
10-Year Revenue Growth per Share128.33%
5-Year Revenue Growth per Share32.72%
3-Year Revenue Growth per Share12.58%
5-Year Operating CF Growth per Share-136.26%
3-Year Operating CF Growth per Share-111.23%
10-Year Net Income Growth per Share-257.83%
5-Year Net Income Growth per Share-403.23%
3-Year Net Income Growth per Share-2.32%
10-Year Shareholders Equity Growth per Share251.02%
5-Year Shareholders Equity Growth per Share109.75%
3-Year Shareholders Equity Growth per Share-5.96%
Receivables Growth-24.00%
Asset Growth-6.02%
Book Value per Share Growth-7.07%
Debt Growth1.76%
R&D Expense Growth-1.11%
SGA Expenses Growth12.42%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 13,279,606.242, captures the company's total value, considering both debt and equity. Income quality, 0.20, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.71, gauges operational efficiency, while the research and development to revenue, 16.08%, highlights investment in innovation. The ratio of intangibles to total assets, 24.70%, indicates the value of non-physical assets, and capex to operating cash flow, 297.97%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value13,279,606.242
Income Quality0.20
Sales General and Administrative to Revenue0.71
Research and Development to Revenue16.08%
Intangibles to Total Assets24.70%
Capex to Operating Cash Flow297.97%
Capex to Revenue-10.62%
Capex to Depreciation-107.23%
Stock-Based Compensation to Revenue0.55%
Graham Number0.03
Return on Tangible Assets-9.44%
Graham Net Net0.02
Working Capital6,682,027
Tangible Asset Value7,221,962
Net Current Asset Value6,509,476
Average Receivables1,324,455
Average Payables192,990.5
Days Sales Outstanding95
ROIC-9.64%
ROE-0.08%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.64, and the price to book ratio, 3.64, reflect the market's valuation relative to the company's book value. The price to sales ratio, 6.18, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -50.12, and price to operating cash flows, -136.76, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.64
Price to Book Ratio3.64
Price to Sales Ratio6.18
Price Cash Flow Ratio-136.76
Price Earnings to Growth Ratio-1.48
Enterprise Value Multiple-39.66
Price Fair Value3.64
Price to Operating Cash Flow Ratio-136.76
Price to Free Cash Flows Ratio-50.12
Price to Tangible Book Ratio1.95
Enterprise Value to Sales3.02
Enterprise Value Over EBITDA-11.48
EV to Operating Cash Flow-84.57
Earnings Yield-4.03%
Free Cash Flow Yield-3.23%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Resonance Health Limited (RHT.AX) on the ASX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -32.940 in 2024.

What is the ticker symbol of Resonance Health Limited stock?

The ticker symbol of Resonance Health Limited stock is RHT.AX.

What is company IPO date?

IPO date of Resonance Health Limited is 2000-01-02.

What is company current share price?

Current share price is 0.077 AUD.

What is stock market cap today?

The market cap of stock today is 34410761.000.

What is PEG ratio in 2024?

The current -1.482 is -1.482 in 2024.

What is the number of employees in 2024?

In 2024 the company has 18.